A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
Taiho Oncology, Inc.
Seagen Inc.
Qurient Co., Ltd.
Novartis
OncoC4, Inc.
NextCure, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc